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Purpose
The T-box family transcription factor Brachyury is over-
expressed in a variety of human carcinomas, including
lung, breast, colon, ovarian and prostate. Brachyury has
been shown to promote epithelial to mesenchymal transi-
tion (EMT) in tumor cells, a critical step in the path to
metastasis. An HLA-A2 epitope of Brachyury has been
shown to expand human T cells that are capable of lysing
Brachyury-expressing tumor cells in an HLA-dependent
manner. A phase I clinical trial is ongoing at the NCI
using a recombinant yeast Brachyury vaccine. We have
previously demonstrated that agonist epitopes of tumor-
associated antigens are more effective than native
epitopes at activating antigen-specific T cell responses.
The current study sought to identify an agonist of the
Brachyury HLA-A2 epitope in order to increase T cell
activation and tumor lysis.
Experimental design
A novel agonist epitope of Brachyury was generated by
residue substitution of the native epitope. Characterization
of this epitope as an agonist included; comparison of
HLA-A2 binding affinity and stability, interferon-g produc-
tion by epitope-specific T cell lines, FACS analysis of acti-
vation markers, as well as Brachyury and HLA-A2 specific
lysis of tumor cells. The presence of Brachyury-specific
T cells in cancer patients that recognize the agonist
peptide was determined by ELISPOT.
Results
The agonist epitope was shown to bind HLA-A2 with
higher avidity and stability than the native. PBMC from
colon and ovarian cancer patients reacted to the agonist
peptide in an ELISPOT assay. Tetramer staining revealed
Brachyury agonist-specific T cells in the PBMC of a pros-
tate cancer patient after in vitro stimulation with the
agonist peptide. T cell lines generated from both the native
and agonist epitopes produced higher levels of interferon-g
in response to stimulation with the agonist epitope, and
they also expressed higher levels of intracellular Ki-67 and
perforin. The agonist-specific T cell line lysed a variety of
Brachyury-expressing tumor cells more efficiently.
Conclusions
An agonist epitope for Brachyury has been identified that,
as compared to the native epitope, increased T cell activa-
tion and cytotoxic activity against tumor cells expressing
native Brachyury. A T cell line generated with the agonist
peptide displayed increased activation (Ki67, perforin) and
cytotoxic activity upon subsequent stimulation with the
peptide. This study supports the use of the Brachyury
agonist epitope as a cancer vaccine strategy.
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